Stanford researchers in the Goldberg lab have developed a novel method for targeted gene therapy delivery to retinal astrocytes for the treatment of glaucoma and other optic neuropathies.
Stanford researchers in the Goldberg lab have discovered two novel gene therapy targets for the treatment of glaucoma and other optic neuropathies. Glaucoma is the leading cause of irreversible blindness world-wide, affecting millions of adults in the United States alone.
Stanford inventors have developed TrueImage, a machine learning algorithm to assess the quality of patient images sent in for telemedicine appointments.
Stanford inventors have developed a functionally-graded implant device for the reconstitution of the necrotic area removed after surgical treatment of osteonecrosis of the hip.
Researchers at Stanford have designed a new nanophotonic detector to reduce cost, size and power consumption compared to existing thermal infrared (IR) cameras.
Stanford researchers in the Criddle lab have developed a novel anaerobic membrane bioreactor that enables high flux treatment of wastewater with greatly reduced energy costs.
Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes.
Stanford researchers have developed a novel catheter technology for sensing embolic delivery and reflux as a strategy to eliminate need for X-ray imaging during angiography.
Stanford researchers have developed a platform for identifying highly specific modulators of cancer-associated mutant Histone Acetyltransferase 1 (HAT1) holoenzyme complexes.
Determining a patient's drug susceptibility is currently a lengthy process requiring hundred to millions of cells. Currently, these cells are labelled, frozen or otherwise manipulated in ways that prevent sequential testing against multiple drugs on the same few cells.
To date, there are no treatments to restore neurologic function for the 7 million US patients suffering from chronic ischemic stroke. NR1 therapy provides a novel treatment for this unmet need.
The Zhenan Bao Research Group at Stanford University developed and manufactured a photo-curable, directly patternable, stretchable, and highly conductive polymer that is ideal for bioelectronic applications, and stretchable electronic devices.